title: [Neuroendocrine pancreatic tumors and helpfulness of targeted therapies].
abstract: The neuroendocrine pancreatic tumors are rare tumors, but their incidence is constantly rising. Even if the management of these tumors has to be surgical as soon as possible, the disease is most often metastatic at the stage of the diagnostic. The prognostic and the therapeutic options differ from pancreatic adenocarcinoma. Available treatments have evolved over the last years with recent publications of studies that bring to light the benefits of targeted therapies in this pathology. This has resulted in modifications of both practices and either French and international guidelines. Therefore, we focus on the management of the grade 1 and grade 2 well-differentiated neuroendocrine pancreatic tumors as classified in new WHO classification of neuroendocrine neoplasms published in 2010.
authors.affiliation: CHU de Cochin Port-Royal, service de gastro-entérologue, 75014 Paris, France.
authors.forename: Thibaut
authors.initials: T
authors.lastname: Vaysse
authors.forename: Romain
authors.initials: R
authors.lastname: Coriat
authors.forename: Géraldine
authors.initials: G
authors.lastname: Perkins
authors.forename: Marion
authors.initials: M
authors.lastname: Dhooge
authors.forename: Catherine
authors.initials: C
authors.lastname: Brezault
authors.forename: Stanislas
authors.initials: S
authors.lastname: Chaussade
mesh_terms: D006801:Humans; D058990:Molecular Targeted Therapy; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000556:secondary; D010190:Pancreatic Neoplasms / Q000188:drug therapy*